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Abstract Corticosteroids are potent anti-inflammatory and
immunosuppressive agents which down-regulate cytokine produc-
tion and action. Yet, contradictory results have been reported for
their effects on the interleukin (IL)-4-mediated response. Using
type II Fc receptor for IgE/CD23 as a target gene, here we report
that corticosteroids at 1034^1036 M inhibit the IL-4 signaling
pathway in human primary immune cells by down-regulation of
the IL-4-induced IL-4 receptor expression and STAT6 activa-
tion. Although functional antagonism between steroid receptor
and STAT6 for their transcriptional activity has been recently
described, this is the first report that steroid inhibits the IL-4-
induced STAT6 activity at the level of tyrosine phosphorylation
and target DNA binding. ß 2002 Federation of European Bio-
chemical Societies. Published by Elsevier Science B.V. All
rights reserved.
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1. Introduction
Although corticosteroids have been widely used as a potent
anti-allergic and anti-in£ammatory drug, the e¡ects of ste-
roids on the interleukin (IL)-4-induced allergic response
have been variable and often contradictory [1,2]. Speci¢cally,
both the positive and the negative regulation of the IL-4-in-
duced response such as IgE production and IL-4 receptor
expression, have been reported in di¡erent cell systems for
varying doses of corticosteroids such as hydrocortisone, meth-
ylprednisolone, and dexamethasone [3^5].
Yet, e¡ects of corticosteroids on the PMA- or IL-4-induced
CD23/FcOR II (type II Fc receptor for IgE) expression are
generally found to be inhibitory in both normal and allergic
B cells [6,7]. CD23 serves as an important mediator for allergy
and in£ammation [8,9]. Two isoforms, CD23a and CD23b,
are known in human systems whose expression patterns are
distinct. It has been reported that CD23b is a primary re-
sponse gene induced by IL-4 in human B cells and monocytes
with a fast kinetics independent of on-going protein synthesis
[10]. Thus, the CD23b gene expression serves as a good model
system to study IL-4 signal transduction. Using human im-
mune cells responsive to IL-4 for CD23b induction, we have
investigated the inhibition mechanism of steroid on the IL-4-
induced signal transduction.
In this report, we demonstrate that corticosteroids at 1034^
1036 M inhibit the IL-4-induced cell surface protein and
mRNA expression of CD23 in tonsillar mononuclear cells as
well as established human monocytic or B cell lines, and the
inhibition was synergized with cotreatment with IFN-Q. Nota-
bly, the inhibition was accompanied by the down-regulation
of IL-4 receptor expression and by the suppression of STAT6
activity via decreased tyrosine phosphorylation and reduced
binding to the target DNA such as the GAS sequence of the
CD23b promoter. Together with the recently proposed tran-
scriptional antagonism between glucocorticoid receptor and
STAT6 [11], the results of the present study suggest a new
mode of steroid action for inhibition of IL-4 signal transduc-
tion.
2. Materials and methods
2.1. Cell culture
Human primary immune cells were obtained by isolation from
freshly excised tonsils using Ficoll-Hypaque (Sigma, d = 1.077)
through density gradient centrifugation. Human promonocytic cell
line U937 and Burkitt’s lymphoma B cell line Ramos were from
ATCC. Isolated mononuclear cells (MNCs), U937, or Ramos cells
were cultured in complete RPMI media (Gibco, Grand Island, NY,
USA) containing 10% FBS at 37‡C with 5% CO2. Cells were treated
with IL-4 (RpD; Systems, Minneapolis, MN, USA) with or without
methylprednisolone (1-dehydro-6-methylhydrocortisone, Sigma), or
IFN-Q (RpD Systems).
2.2. Analysis of surface CD23 and IL-4 receptor by £ow cytometry
The surface expression of FcOR II/CD23 on cells was analyzed
employing FACS Calibur (Becton Dickinson, Mountain View, CA,
USA) using mouse anti-human CD23 mAb-PE (Becton Dickinson)
after 24 h culture with IL-4. The expression of IL-4 receptor alpha
was analyzed by staining cells with monoclonal anti-IL-4 receptor Ab
(M56) and then with goat anti-mouse IgG-FITC (Sigma) as described
[12]. The surface protein levels were expressed as the mean £uores-
cence intensity (MFI). Each experiment was repeated several times
and the values represent a mean of two independent determinations.
2.3. Analysis of mRNA levels of CD23 and IL-4 receptor by Northern
blot
Total cytoplasmic RNAs were isolated using 4 M guanidinium iso-
thiocyanate and 5 M cesium chloride through ultracentrifugation.
RNAs were separated on a 1% agarose gel, transferred to nylon
membranes, and hybridized with a [32P]-labeled probe of FcOR II/
CD23 or IL-4 receptor cDNA as described [10,12]. Blots were re-
probed with the adenosyl phosphoribosyl transferase (APRT) probe
as an internal control [13]. A representative blot for each experiment
is shown.
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2.4. Electrophoretic mobility shift assay (EMSA)
Preparation of nuclear extracts for EMSA was done after stimu-
lation of cells with IL-4 as described [14]. IL-4RE GAS oligomer,
CD23b GAS1 containing the STAT6 binding site of human CD23b,
was labeled with [32P]dCTP (3 000 Ci/mmol, NEN) by Klenow [15]. In
addition CD23b GAS2 probe (5P-GGTGAATTTCTAAGAAAGG-
GACTGGTGTGAGTAAGGAG-3P) representing a longer native se-
quence of human CD23b promoter (3234 to 3199) containing both
the STAT6 binding site and the activator protein-1 (AP-1) binding site
was also used. The extracts (5^10 Wg) were incubated with the labeled
oligomer in the binding bu¡er for 20 min at room temperature. Mo-
bility shift of the oligomer was then analyzed by 5% PAGE in 0.5U
TBE bu¡er.
2.5. Immunoprecipitation and immunoblotting
Cells were pretreated with corticosteroid for various durations and
stimulated with IL-4, after which total cell extracts were prepared
using a lysis bu¡er containing 1% NP40 as described [16]. The extracts
were immunoprecipitated with mouse monoclonal anti-phosphotyro-
sine (4G10) or rabbit polyclonal anti-STAT6 Abs (UBI, Lake Placid,
NY, USA), and then with respective secondary antibody conjugated
with agarose. After fractionation on a 10% denaturing SDS^PAGE
and transfer to PVDF membranes, immunoblotting was performed
using anti-STAT6, anti-IL-4 receptor (RpD Systems), anti-Jak1
(UBI), or anti-phosphotyrosine antibodies as indicated. After strip-
ping, the blot was reprobed with anti-STAT6 Ab. All blots were
developed using an ECL detection kit (Amersham).
3. Results and discussion
3.1. Corticosteroid inhibits the IL-4-induced CD23 surface
expression: synergistic action with IFN-Q
The up-regulation of CD23 expression is one of the major
phenotypical changes induced by IL-4 in B cells and mono-
cytes [17]. In fact, CD23 is regarded as a di¡erentiation anti-
gen important for IgE production by B cells, for allergen
uptake and presentation by antigen presenting cells, and for
in£ammation by accessory cells including basophils and eo-
sinophils [8,9,18,19]. Using tonsillar mononuclear cells, we
have observed that a corticosteroid, methylprednisolone, ef-
fectively suppresses the IL-4-induced CD23 up-regulation in a
dose-dependent manner (60^85% inhibition at 1034^1036M).
IFN-Q, a known antagonist of the IL-4-induced CD23 expres-
sion, acted synergistically with the steroid, and resulted in a
nearly complete suppression (90^95%) upon cotreatment (Fig.
1A). Such inhibitory e¡ects of the corticosteroid were also
observed with U937 and Ramos, established monocytic and
B cell lines, respectively, which were both responsive to IL-4
for the induction of CD23 expression (Fig. 1B,C). A similar
inhibitory e¡ect was obtained with other corticosteroids, hy-
drocortisone or dexamethasone at 1034^1037M (data not
shown).
3.2. Inhibition of the IL-4-induced CD23 mRNA by
corticosteroid
To investigate the mechanism of CD23 inhibition by ste-
roid, we have examined the regulatory e¡ect of steroid on
CD23 mRNA level and the kinetics of inhibition. As shown
in Fig. 2, the steroid suppressed the IL-4-induced CD23
mRNA levels in a time-dependent manner. Contrary to
IFN-Q whose inhibitory e¡ect was not observed during the
early time of IFN-Q treatment ([20], Fig. 2A, lanes 2 vs. 4),
the suppressive e¡ect of corticosteroid appeared by 4 h and
became signi¢cant by 16 h (Fig. 2A, lanes 2 vs. 3 and 7 vs. 8).
The synergistic inhibition was noted upon cotreatment of cells
with steroid and IFN-Q (lanes 7 to 10). A similar result was
obtained with U937 cells for the suppressive e¡ect of steroid
on CD23 mRNA (Fig. 2B). These results indicate that steroid
inhibition of the IL-4-induced CD23 protein expression ob-
served in Fig. 1 proceeds via down-regulation of CD23
mRNA in these immune cells.
3.3. Down-regulation of IL-4 receptor expression by
corticosteroid
As one of the mechanisms of the steroid-mediated inhibi-
Fig. 1. Inhibition of the IL-4-induced surface FcOR II/CD23 expression by steroid (ST) in various human immune cells. Tonsil MNCs (A),
U937 cells (B), and Ramos cells (C) were seeded in 24-well plates (2U105 cells/well), and treated with IL-4 (5 ng/ml), methylprednisolone
(1034^1036 M), or IFN-Q (1000 U/ml) as indicated. After 24 h culture, FACScan analysis of surface CD23 was performed using monoclonal
anti-CD23-PE as in Section 2. vMFI was calculated as MFI of anti-CD23-PE-stained sample 3 MFI of unstained control.
6
Fig. 2. Inhibition of the IL-4-induced CD23 mRNA expression by
steroid. A: Inhibition kinetics and the e¡ect of IFN-Q cotreatment
in tonsillar mononuclear cells. Mononuclear cells (1U108) were
treated with IL-4 (5 ng/ml), methylprednisolone (1035 M), and
IFN-Q (2000 U/ml) for the indicated time periods. Cells were har-
vested for RNA isolation and the subsequent Northern analysis
using the full-length cDNA probe of CD23 as described. Top:
Northern autoradiogram. Bottom: EtBr-stained RNA gel. B: Inhib-
itory e¡ect of steroid on the IL-4-induced CD23 mRNA expression
in U937 cells. U937 cells (1U107) were treated with IL-4 (5 ng/ml)
and methylprednisolone (1035 M). The total RNAs were isolated
and subjected to Northern analysis (top). The membrane was
stripped and reprobed with an APRT probe as described (bottom).
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tion of the IL-4-induced CD23 expression, we have next ex-
amined e¡ects of steroid on the modulation of IL-4 receptor
expression. Although IL-4 receptor has been shown to be
subject to regulation by cytokines and steroid, contradictory
results have been obtained depending on the cell types and
dose of steroid [5,12]. Using human tonsillar mononuclear
cells, we have observed that 1035^1036M methylprednisolone
e¡ectively down-regulates the IL-4-induced IL-4 receptor ex-
Fig. 3. Down-regulation of the IL-4-induced IL-4 receptor by steroid. A: Inhibitory e¡ect of steroid on the surface IL-4 receptor expression.
Tonsillar mononuclear cells (1U106) were treated with IL-4 (5 ng/ml), methylprednisolone (1035 M), and IFN-Q (1000 U/ml) for 24 h. Cells
were harvested and stained with mouse monoclonal anti-human IL-4RK Ab (M56) and then with anti-mouse-IgG-FITC as described. vMFI
was calculated as MFI of anti-IL-4R Ab and anti-mouse IgG-FITC ^ MFI of cells stained with anti-mouse IgG-FITC alone. B: Inhibitory ef-
fect of steroid on the IL-4 receptor mRNA expression ^ coordinated regulation with CD23 mRNA. Mononuclear cells (1U108) were treated
with IL-4 (5 ng/ml), IFN-Q (1000 U/ml) or steroid (1036 M) and cultured for 16 h. Total RNAs were isolated and processed for Northern anal-
ysis. The blot was probed with an IL-4R cDNA probe (top) and then with a CD23 cDNA probe after stripping (middle). The EtBr-stained
RNA gel is also shown (bottom).
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pression (Fig. 3A). Such inhibitory e¡ect was also manifested
at the IL-4 receptor mRNA level (Fig. 3B). While IFN-Q (1000
U/ml) induced a modest inhibition of the IL-4-induced IL-4
receptor levels, steroid at 1035^1036 M caused a more potent
inhibition. Upon cotreatment, IFN-Q and steroid acted in a
synergistic manner to further reduce the IL-4 receptor level. It
should be noted that the modulation of IL-4 receptor mRNA
coordinately occurred with that of CD23 mRNA as indicated
in earlier studies [21]. This suggests that the suppressive e¡ect
of corticosteroid and/or IFN-Q on CD23 expression is partly
mediated via inhibition of IL-4 receptor gene expression by
these agents.
3.4. Suppression of STAT6 activity by corticosteroid
The IL-4 signal transduction leading to CD23 gene expres-
sion is thought to proceed via STAT6-dependent pathways
[22,23]. STAT6 acts as a signal transducer immediately down-
stream of IL-4 receptor activation via tyrosine phosphoryla-
tion by Jak-1 and Jak-3, IL-4 receptor-associated tyrosine ki-
nases [24]. In fact, role of STAT6 in the IL-4-induced gene
expression has been well established during recent years.
Thus, we have examined whether STAT6 is a target of
steroid action to suppress CD23 gene activation. Steroid
when cotreated to cells with IL-4 for 10^30 min did not exert
any inhibitory e¡ects on the IL-4-induced STAT6 binding to
Fig. 4. Suppression of the IL-4-induced STAT6 activation by steroid: reduced DNA binding and tyrosine phosphorylation of STAT6 by
steroid. A: Tonsillar mononuclear cells (1U108) were treated with steroid (1035 M) for various durations prior to the stimulation with IL-4
(5 ng/ml) for 30 min. Cells were harvested and nuclear extracts were prepared to perform EMSA using the CD23b GAS1 probe as described in
the text. B: The total cell lysates were prepared from the same cultures as in A. The lysates (1 mg) were subjected to immunoprecipitation with
anti-STAT6 Ab followed by immunoblotting with anti-phosphotyrosine Ab and then with anti-STAT6 Ab as described.
Fig. 5. Suppressive e¡ects of steroid on the IL-4-induced tyrosine phosphorylation of Jak1 and IL-4 receptor. Tonsillar mononuclear cells
(1U108) were treated with steroid (1035M) for various durations. Cells were then stimulated with IL-4 for 10 min, after which cell extracts
were prepared for the analysis of tyrosine phosphorylation and protein level of Jak1, IL-4 receptor, and STAT6 by immunoprecipitation and
Western blot.
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the CD23b GAS1 sequence (data not shown). While the IL-4-
induced STAT6 activation occurs generally within a few min-
utes, reaches to maximum during 20^40 min, and then signi¢-
cantly declines after 2 h [25], the inhibitory e¡ect of steroid on
the IL-4-induced CD23 gene expression is prominent after 4 h
(Fig. 2). In order to assess the e¡ect of steroid on the IL-4-
induced STAT6 activity, we have thus pretreated cells with
steroid for 3^24 h and then stimulated with IL-4 for 30
min. Under these conditions, a signi¢cant inhibition of the
IL-4-induced STAT6 activity was observed for target DNA
binding (Fig. 4A). This appears due to the reduced tyrosine
phosphorylation of STAT6 (Fig. 4B). In order to further de-
lineate the molecular mechanism of steroid action for STAT6
inhibition, we have analyzed the e¡ect of steroid on the acti-
vation status of Jak1 and IL-4 receptor, upstream components
of STAT6 in IL-4 signaling. As shown in Fig. 5, steroid ef-
fectively suppressed the IL-4-induced tyrosine phosphoryla-
tion of STAT6 with concomitant inhibition of Jak-1 and
IL-4 receptor activation as shown by speci¢c abrogation of
tyrosine phosphorylation of these molecules. The results indi-
cate that the corticosteroid-induced inhibition of IL-4 signal-
ing occurs via the suppression of STAT6 activation by block-
ing tyrosine phosphorylation of Jak1 and IL-4 receptor, which
would inhibit docking of STAT6 to the receptor and the sub-
sequent phosphorylation of STAT6, nuclear translocation,
and the target DNA binding. A steroid-inducible STAT,
such as Jak-binding protein/suppressor of cytokine signaling/
STAT-induced STAT inhibitor may be involved in this pro-
cess [26^28]. In addition, a more direct role of steroid on
STAT6 suppression during IL-4-induced CD23 gene expres-
sion is suggested by data in Fig. 6. That is, when an extended
native promoter sequence of CD23b (3234 to 3199) which
contains the STAT6 site and the adjacent AP-1 site was used,
the inhibition of STAT6 binding was clearly observed even
when cells were simultaneously treated with IL-4 and steroid
for 10^40 min. While the mechanism of the observed inhibi-
tion is not clear at present, a possible role of AP-1 sequence in
mediating steroid action via interaction with steroid receptor
is to be examined.
Taken together, these results suggest that a direct inhibition
of corticosteroid on the STAT6 binding to CD23b promoter
as well as an indirect action through the induction of a STAT
inhibitor are both responsible for the inhibitory action of
steroid on the IL-4-induced CD23 gene activation. As much
as the role of STAT6 has been implicated in the induction of
IL-4 receptor gene expression [29], it is possible that down-
modulation of IL-4 receptor by steroid observed upon pro-
longed treatment with IL-4 in Fig. 3 occurs via inhibition of
the IL-4-induced STAT6 activity. Unlike murine systems,
however, a de¢nitive role of STAT6 in regulating human
IL-4 receptor gene expression has not been demonstrated,
partly due to the unavailability of the exact promoter struc-
ture of the human IL-4 receptor. Still, the observed down-
regulation of IL-4 receptor by steroid would in part account
for the suppressive action of corticosteroid on the IL-4-medi-
ated CD23 induction and other cellular responses occurring in
later phase of IL-4 action.
Modulation of STAT activity by steroids has been sug-
gested for functional cooperation as well as antagonism be-
tween STATs and steroid receptors through reciprocal regu-
lation of their transcriptional activities as observed with
STAT1, STAT3, STAT5, and STAT6 [11,30^33]. In particu-
lar, Biola et al. [11] have recently reported that the transcrip-
tional antagonism between the glucocorticoid receptor and
STAT6 involves physical interaction of the two molecules
without change in DNA binding of STAT6. The present re-
port is the ¢rst to demonstrate that corticosteroid targets
STAT6 at the level of tyrosine phosphorylation and DNA
binding, which suggests a novel mode of steroid action regu-
lating IL-4 signal transduction. Identi¢cation of steroid-in-
duced STAT inhibitors blocking tyrosine phosphorylation of
STAT6 as well as the elucidation of inhibition mechanism of
steroid action to directly suppress the STAT6 binding to the
CD23b promoter warrant further investigation.
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